Thanyaphong Na Nakorn

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

Jesús F. San Miguel, Vânia Hungria, Sung‐Soo Yoon et al. · The Lancet Oncology · 2014 · 781 citations

Hematological Malignancy, Double-blind Phase 3, Medicine +9

Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial

Meletios Α. Dimopoulos, Francesca Gay, Fredrik Schjesvold et al. · The Lancet · 2018 · 231 citations · Full text

Regenerative Medicine, Cell Therapy, Transplantation +7

Myeloerythroid-restricted progenitors are sufficient to confer radioprotection and provide the majority of day 8 CFU-S

Thanyaphong Na Nakorn, David Traver, Irving L. Weissman et al. · Journal of Clinical Investigation · 2002 · 190 citations · Full text

Characterization of mouse clonogenic megakaryocyte progenitors

Thanyaphong Na Nakorn, Toshihiro Miyamoto, Irving L. Weissman · Proceedings of the National Academy of Sciences · 2002 · 165 citations · Full text

Common Myeloid Progenitors, Cell Therapy, Developmental Biology +10

Myeloerythroid-restricted progenitors are sufficient to confer radioprotection and provide the majority of day 8 CFU-S

Thanyaphong Na Nakorn, David Traver, Irving L. Weissman et al. · Journal of Clinical Investigation · 2002 · 165 citations · Full text

Day 8, Myeloerythroid-restricted Progenitors, Bone Marrow Failure +15